2025
Turmimax® BIO 84-day clinical study results published
A prospective, randomized, double-blind, placebo-controlled study in 100 adults with mild-to-moderate knee OA reported a 50.37% reduction in total WOMAC score by Day 84.
News & press
News, publications & events
Press releases, peer-reviewed publications, trade shows and formulation insights from the Turmimax® BIO team.
Press releases
Recent announcements
2024
Hassan facility FSSC 22000 recertification
Star Hi Herbs' Hassan manufacturing facility completed its FSSC 22000 audit for the manufacture of herbal extracts and probiotic products, valid until 10 December 2028.
2023
Turmimax® BIO featured in Brazilian Journal of Biology
Peer-reviewed publication reporting antiproliferative activity and apoptosis-inducing mechanism of Turmimax® BIO on HeLa cell lines (IC50 87.89 µg/mL).
2022
Anti-inflammatory potential published in AJBB
American Journal of Biochemistry and Biotechnology paper documenting in-vivo and in-vitro anti-inflammatory activity of Turmimax® BIO.
Trade shows & events
Meet us on the road
The Turmimax® BIO team exhibits at international nutraceutical and ingredient trade shows across Asia, Europe and North America. To schedule a meeting during an upcoming event, reach out via the contact page and our commercial team will confirm availability.
Request a meeting →Articles & insights
What we're writing about
- Water-dispersible curcumin vs standard curcumin: what is the difference?
- Turmimax® BIO bioavailability explained
- How to formulate curcumin into gummies, powders and beverages
- Curcumin dosage: understanding clinically studied use levels
- Why upto 95% curcuminoid standardisation matters
- The 2026 joint-health ingredient market: trends & opportunities
- Curcumin for joint-health formulations: what formulators should evaluate
- How inflammatory biomarkers are used in joint-health research